Adicet Bio (LTS:0HX7) Construction In Progress : $0.23 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Construction In Progress?

Adicet Bio's quarterly construction in progress declined from Sep. 2024 ($1.87 Mil) to Dec. 2024 ($0.20 Mil) but then increased from Dec. 2024 ($0.20 Mil) to Mar. 2025 ($0.23 Mil).

Adicet Bio's annual construction in progress declined from Dec. 2022 ($9.29 Mil) to Dec. 2023 ($0.27 Mil) and declined from Dec. 2023 ($0.27 Mil) to Dec. 2024 ($0.20 Mil).

Adicet Bio Construction In Progress Historical Data

The historical data trend for Adicet Bio's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Construction In Progress Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

1.09

13.01

9.29

0.27

0.20

Adicet Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															0.37	0.35	1.87	0.20	0.23

Adicet Bio Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Adicet Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

ACET:USA

Address

131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Headlines

No Headlines